drugset
Drugs / AUY922
last change Apr 2021 re-read 2 minutes ago

AUY922

also known as AUY · Intravenous drug · Luminespib · NVP-AUY922

Small molecule

Developed for
non-small cell lung carcinoma · gastric cancer · gastrointestinal stromal tumor · HER2 positive breast carcinoma · breast cancer · cancer · cancer of unknown primary site · colon adenocarcinoma
+11 more · estrogen-receptor positive breast cancer · gastroesophageal cancer · lung adenocarcinoma · lymphoma · metastatic malignant neoplasm · metastatic neoplasm · myeloproliferative neoplasm · pancreatic adenocarcinoma · rectum adenocarcinoma · refractory plasma cell neoplasm · squamous cell lung carcinoma
Investigated by
Novartis Pharmaceuticals · Novartis · National Taiwan University Hospital · SCRI Development Innovations, LLC · Bezmialem Vakif University · Chang Gung Memorial Hospital
+18 more · China Medical University Hospital · Dale Shepard, MD, PhD · Jonsson Comprehensive Cancer Center · M.D. Anderson Cancer Center · Mackay Memorial Hospital · Massachusetts General Hospital · Memorial Sloan Kettering Cancer Center · National Cancer Institute (NCI) · National Cheng-Kung University Hospital · National Health Research Institutes, Taiwan · Northwestern University · Robert H. Lurie Cancer Center · Swedish Medical Center · Taichung Veterans General Hospital · Taipei Veterans General Hospital, Taiwan · Texas Tech University Health Sciences Center, El Paso · Translational Research in Oncology · University Health Network, Toronto

Trials 24 · a red edge is where a trial was stopped

today NCT06454825 · Ph 4 NCT01784640 · Ph 1 NCT01922583 · Ph 2 NCT01772797 · Ph 1 NCT01752400 · Ph 2 NCT01613950 · Ph 1 NCT01646125 · Ph 2 NCT01485536 · Ph 2 NCT01668173 · Ph 2 NCT01484860 · Ph 2 NCT01404650 · Ph 2 NCT01402401 · Ph 2 NCT01389583 · Ph 2 NCT01602627 · Ph 1 NCT01361945 · Ph 1/2 NCT01259089 · Ph 1/2 NCT01294826 · Ph 1 NCT01226732 · Ph 1 NCT01124864 · Ph 2 NCT01271920 · Ph 1/2 NCT01084330 · Ph 2 NCT01132625 · Ph 1 NCT00708292 · Ph 1/2 NCT00526045 · Ph 1/2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT01784640 Jan 2014 → Oct 2018 non-small cell lung carcinoma, squamous cell lung carcinoma Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT01772797 Jun 2013 → Jan 2016 non-small cell lung carcinoma Novartis Pharmaceuticals Completed No outcome recorded
Phase 1 NCT01613950 Dec 2012 → Mar 2014 gastric cancer Novartis Pharmaceuticals Completed No outcome recorded
Phase 1 NCT01602627 Sep 2011 → Feb 2012 cancer of unknown primary site Dale Shepard, MD, PhD Terminated No outcome recorded
Phase 1 NCT01294826 Feb 2011 → May 2015 colon adenocarcinoma, rectum adenocarcinoma Swedish Medical Center Completed No outcome recorded
Phase 1 NCT01226732 Nov 2010 → Jul 2013 metastatic malignant neoplasm SCRI Development Innovations, LLC Completed No outcome recorded
Phase 1 NCT01132625 Nov 2008 → May 2012 cancer Novartis Pharmaceuticals Completed No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT01361945 Jul 2011 → Aug 2012 HER2 positive breast carcinoma, estrogen-receptor positive breast cancer Texas Tech University Health Sciences Center, El Paso Withdrawn No outcome recorded
Phase 1/2 NCT01259089 Apr 2011 → Jun 2013 lung adenocarcinoma Northwestern University Completed No outcome recorded
Phase 1/2 NCT01271920 Sep 2010 → Oct 2013 HER2 positive breast carcinoma Novartis Pharmaceuticals Completed No outcome recorded
Phase 1/2 NCT00708292 Jul 2008 → Jan 2011 refractory plasma cell neoplasm Novartis Pharmaceuticals Completed No outcome recorded
Phase 1/2 NCT00526045 Jul 2007 → Apr 2012 breast cancer, hematopoietic and lymphoid cell neoplasm Novartis Pharmaceuticals Completed No outcome recorded
Phase 211 trials
Phase 2 NCT01922583 Jan 2014 → Feb 2017 non-small cell lung carcinoma National Taiwan University Hospital Completed No outcome recorded
Phase 2 NCT01752400 Jan 2013 → Jun 2017 non-small cell lung carcinoma Massachusetts General Hospital Completed No outcome recorded
Phase 2 NCT01646125 Nov 2012 → Nov 2015 non-small cell lung carcinoma Novartis Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT01485536 Aug 2012 → Nov 2015 lymphoma M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 2 NCT01668173 Aug 2012 → May 2015 myeloproliferative neoplasm Memorial Sloan Kettering Cancer Center Terminated No outcome recorded
Phase 2 NCT01484860 Jan 2012 → Aug 2013 metastatic neoplasm, pancreatic adenocarcinoma University Health Network, Toronto Terminated No outcome recorded
Phase 2 NCT01404650 Dec 2011 → Feb 2015 gastrointestinal stromal tumor SCRI Development Innovations, LLC Completed No outcome recorded
Phase 2 NCT01402401 Nov 2011 → Jun 2013 gastric cancer Novartis Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT01389583 Oct 2011 → May 2015 gastrointestinal stromal tumor National Health Research Institutes, Taiwan Unknown No outcome recorded
Phase 2 NCT01124864 Oct 2010 → Aug 2014 non-small cell lung carcinoma Novartis Pharmaceuticals Completed No outcome recorded
Phase 41 trial
Phase 4 NCT06454825 Apr 2020 → Apr 2021 disorder of facial skeleton Bezmialem Vakif University Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 25 sources stand behind the page.

FieldValueCited text
Known as AUY 922 “A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors” NCT01226732 ↗
24

“AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally” NCT01361945 ↗

NCT01402401 ↗

NCT01226732 ↗

NCT01132625 ↗

NCT01613950 ↗

NCT01271920 ↗

NCT00526045 ↗

NCT01922583 ↗

NCT01602627 ↗

NCT01404650 ↗

NCT01484860 ↗

NCT01752400 ↗

NCT00708292 ↗

NCT01084330 ↗

NCT01294826 ↗

NCT01772797 ↗

NCT01124864 ↗

NCT01646125 ↗

NCT01784640 ↗

NCT01389583 ↗

NCT01668173 ↗

NCT01361945 ↗

NCT01485536 ↗

NCT01259089 ↗
Known as AUY “BACKGROUND: NVP-AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells.” PMID 25809731 ↗ Mar 2015
Known as Intravenous drug ClinicalTrials.gov intervention name — accepted as the source's own label NCT06454825 ↗
Known as Luminespib “BACKGROUND: NVP-AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells.” PMID 25809731 ↗ Mar 2015
Known as NVP-AUY922 “BACKGROUND: NVP-AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells.” PMID 25809731 ↗ Mar 2015
Action Inhibit “Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.” PMID 25809731 ↗ Mar 2015
Modality Small molecule “AUY922 is a novel isoxazole-based HSP90 inhibitor.” NCT01484860 ↗
Route Intravenous “AUY922 administered intravenously” NCT00526045 ↗